Oragenics gets fourth patent for MU1140

By Elaine Rigoli

Tampa, Fla., Aug. 7 - Oragenics, Inc. announced that the U.S. Patent Office has issued a fourth patent (No. 7,067,125), that further describes the composition and uses of the company's exclusively licensed antibiotic peptide, MU1140.

The patent claims include uses of the antimicrobial peptide for the treatment and prevention of bacterial infections.

"MU1140 represents a major new class of antibiotics and one day could become a clinically useful tool against those bacteria that have grown resistant to existing antibiotics," the chief scientific officer and the inventor of the patented MU1140 technology, Jeffrey Hillman, said in a news release.

Oragenics plans to complete by the end of this year the preclinical tests necessary to begin a human clinical trial.

Oragenics is a biopharmaceutical company based in Alachua, Fla.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.